1. In Vivo
  2. >>Archive

Berg's Back To Biology Approach

 
• By Melanie Senior

Berg compares diseased and healthy tissue to drive drug discovery.

To overcome the biases of input data, Berg LLC's President and CEO Niven Narain asserts, “We start with a hypothesis-agnostic, data-driven model.” All the data are deconstructed down to the very basics, stripped of any assumptions, including around parameterization, for instance (choosing which variables to look at). Then the data are re-constructed again – looking at linkages and correlations, including among different data types.

Put simply, BERG compares diseased and healthy tissue and hones in on the differences to drive new drug discovery. That’s...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from In Vivo

Rising Leaders 2025: Doxie Jordan, From UNC Graduate To Global Market Strategist

 
• By Jo Shorthouse

Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy

Podcast: Brain+ CEO Discusses “Groundbreaking” Potential Of CST Assistant For Dementia Patients

 
• By Anabel Costa-Ferreira

Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By Jo Shorthouse

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.